In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Ovid Therapeutics Inc (NASDAQ: OVID) closed the day trading at $1.48 down -5.73% from the previous closing price of $1.57. In other words, the price has decreased by -$5.73 from its previous closing price. On the day, 2.05 million shares were traded. OVID stock price reached its highest trading level at $1.6099 during the session, while it also had its lowest trading level at $1.46.
Ratios:
For a better understanding of OVID, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Oppenheimer on October 09, 2025, initiated with a Outperform rating and assigned the stock a target price of $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 105242080 and an Enterprise Value of 80994080. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.83 while its Price-to-Book (P/B) ratio in mrq is 1.89. Its current Enterprise Value per Revenue stands at 12.178 whereas that against EBITDA is -1.966.
Stock Price History:
The Beta on a monthly basis for OVID is 0.28, which has changed by 0.24369752 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $2.01, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 16.18%, while the 200-Day Moving Average is calculated to be 122.05%.
Shares Statistics:
Over the past 3-months, OVID traded about 3.23M shares per day on average, while over the past 10 days, OVID traded about 3040950 shares per day. A total of 71.11M shares are outstanding, with a floating share count of 59.52M. Insiders hold about 16.29% of the company’s shares, while institutions hold 35.31% stake in the company. Shares short for OVID as of 1759190400 were 680035 with a Short Ratio of 0.21, compared to 1756425600 on 1274152. Therefore, it implies a Short% of Shares Outstanding of 680035 and a Short% of Float of 1.1400000000000001.
Earnings Estimates
The performance of Ovid Therapeutics Inc (OVID) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.08 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.42 and -$0.46 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.36, with 5.0 analysts recommending between -$0.22 and -$0.64.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $7.39M, while the lowest revenue estimate was $6.4M, resulting in an average revenue estimate of $6.66M. In the same quarter a year ago, actual revenue was $566k
